Cargando…

The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer

The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helfand, Brian T., Paterakos, Michael, Wang, Chi-Hsiung, Talaty, Pooja, Abran, John, Bennett, John, Hall, David W., Lehman, Amy, Aboushwareb, Tamer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/ https://www.ncbi.nlm.nih.gov/pubmed/36048818 http://dx.doi.org/10.1371/journal.pone.0273782

Ejemplares similares

The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center
por: Canter, Daniel J., et al.
Publicado: (2023)

GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality
por: Brooks, Michael A., et al.
Publicado: (2021)

Nanocytological Field Carcinogenesis Detection to Mitigate Overdiagnosis of Prostate Cancer: A Proof of Concept Study
por: Roy, Hemant K., et al.
Publicado: (2015)

A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate Cancer
por: Pearce, Shane M, et al.
Publicado: (2015)

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)
por: Leapman, Michael S., et al.
Publicado: (2017)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
por: Kang, Ho Won, et al.
Publicado: (2016)

The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
por: Kang, Ho Won, et al.
Publicado: (2017)

Diagnosing hereditary cancer predisposition in men with prostate cancer
por: Pritzlaff, Mary, et al.
Publicado: (2020)

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
por: Cyll, Karolina, et al.
Publicado: (2022)

TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease
por: Vickman, Renee E., et al.
Publicado: (2022)

Co-Occurring Gland Angularity in Localized Subgraphs: Predicting Biochemical Recurrence in Intermediate-Risk Prostate Cancer Patients
por: Lee, George, et al.
Publicado: (2014)

Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies
por: Turchan, William Tyler, et al.
Publicado: (2020)

PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
por: Devos, Gaëtan, et al.
Publicado: (2020)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Identification of Potential Predictor of Biochemical Recurrence in Prostate Cancer
por: Wei, Jingchao, et al.
Publicado: (2022)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

A comparison of genetic risk score with family history for estimating prostate cancer risk
por: Helfand, Brian T
Publicado: (2016)

The Excretion of 17-Kestoteroids in Men of Different Age-Groups, with Special Reference to Prostatic cancer
por: Robinson, A. M.
Publicado: (1948)

A Qualitative Study of Urinary 17-Ketosteroids in Normal Males and in Men with Prostatic Disease
por: Robinson, Alice M., et al.
Publicado: (1949)

Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
por: Schreiber, David, et al.
Publicado: (2015)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Prostatitis, Sexually Transmitted Diseases, and Prostate Cancer: The California Men's Health Study
por: Cheng, Iona, et al.
Publicado: (2010)

Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study
por: Park, Dae Hyoung, et al.
Publicado: (2023)

Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer
por: Kok, Dieuwertje E. G., et al.
Publicado: (2010)

The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy
por: Murray, Nigel P, et al.
Publicado: (2018)

Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy
por: Peng, Chao, et al.
Publicado: (2019)

Does Prostate Volume Correlate with Vitamin D Deficiency Among Men Undergoing Prostate Biopsy?
por: Murphy, Adam B., et al.
Publicado: (2016)

Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy
por: Hackett, Cian, et al.
Publicado: (2014)

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
por: Waterhouse, Robert L., et al.
Publicado: (2019)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence
por: Pavel, Anca Gabriela, et al.
Publicado: (2022)

A modeling study to estimate prostate cancer‐specific mortality on active surveillance for men with favorable intermediate‐risk prostate cancer: Results from the SEARCH cohort
por: Kuhlmann, Paige K., et al.
Publicado: (2023)

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review
por: Laukhtina, Ekaterina, et al.
Publicado: (2021)

Racial Disparities in Prostate Cancer Incidence, Biochemical Recurrence, and Mortality
por: Bock, Cathryn H., et al.
Publicado: (2011)

Biochemical Recurrence in Gleason Score 7 Prostate Cancer in Korean Men: Significance of the Primary Gleason Grade
por: Ro, Yun Kwan, et al.
Publicado: (2012)

A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2014)

Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men
por: Moustsen, Ida Rask, et al.
Publicado: (2019)

Predictors of urgency improvement after Holmium laser enucleation of the prostate in men with benign prostatic hyperplasia
por: Hur, Won Sok, et al.
Publicado: (2016)

Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_42tirke6hbq9sh07trd8rgvtpe